{"organizations": [], "uuid": "2d241989a0a7117b2924a5bb1e2d4ab67f968cc9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "https://si.wsj.net/public/resources/images/BN-XF147_3kmIm_TOP_20180129051639.jpg", "site_section": "https://www.wsj.com/europe", "section_title": "The Wall Street Journal &amp; Breaking News, Business, Financial and Economic News, World News and Video", "url": "https://www.wsj.com/articles/sanofi-to-pay-4-85-billion-for-biotech-focused-on-small-antibodies-1517221477", "country": "US", "domain_rank": 387, "title": "Sanofi to Pay $4.85 Billion for Biotech Focused on Small Antibodies", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-29T13:24:00.000+02:00", "replies_count": 0, "uuid": "2d241989a0a7117b2924a5bb1e2d4ab67f968cc9"}, "author": "Noemie Bisserbe", "url": "https://www.wsj.com/articles/sanofi-to-pay-4-85-billion-for-biotech-focused-on-small-antibodies-1517221477", "ord_in_thread": 0, "title": "Sanofi to Pay $4.85 Billion for Biotech Focused on Small Antibodies", "locations": [], "entities": {"persons": [], "locations": [{"name": "paris", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}, {"name": "denmark", "sentiment": "none"}], "organizations": [{"name": "ablynx nv", "sentiment": "negative"}, {"name": "sanofi", "sentiment": "negative"}, {"name": "sanofi sa", "sentiment": "negative"}, {"name": "novo nordisk", "sentiment": "none"}, {"name": "novo nordisk a/s", "sentiment": "none"}, {"name": "bioverativ inc", "sentiment": "none"}, {"name": "ablynx", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "PARIS—Sanofi SA said Monday it would buy Belgian biotech Ablynx NV for €3.9 billion ($4.85 billion), the French drugmaker’s second acquisition this month after purchasing U.S. hemophilia specialist Bioverativ Inc.\nSanofi will pay €45 a share for Ablynx, which earlier this month rejected a €2.6 billion offer from Denmark’s Novo Nordisk A/S. Novo Nordisk said Monday it won’t be making a revised proposal.\nThe... To Read the Full Story Subscribe Sign In", "external_links": [], "published": "2018-01-29T13:24:00.000+02:00", "crawled": "2018-01-30T00:43:30.034+02:00", "highlightTitle": ""}